Genomics Bioscience & Technology Co

Genomics Bioscience & Technology Co DSCR

The Debt Service Coverage Ratio (DSCR) of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 21, 2026 is -0.29. In the previous year, Debt Service Coverage Ratio (DSCR) was -0.34 — a change of -15.29% (higher).

DSCR

-0.29

YoY

-15.29%

Last updated:

Debt Service Coverage Ratio (DSCR) of Genomics Bioscience & Technology Co is 2025 -0.29 . Debt Service Coverage Ratio (DSCR) of Genomics Bioscience & Technology Co was 2024 -0.34 . It decreases by -15.29% higher compared to the previous year.

The Genomics Bioscience & Technology Co DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2018
1.03 TWD
Jan 1, 2019
1.49 TWD
Jan 1, 2020
-0.16 TWD
Jan 1, 2021
-0.32 TWD
Jan 1, 2022
-0.09 TWD
Jan 1, 2023
-0.34 TWD
Jan 1, 2024
-0.34 TWD
Jan 1, 2025
-0.29 TWD
The Genomics Bioscience & Technology Co DSCR history
YEARDSCRYoY
-0.29-15.29%
-0.34+0.37%
-0.34+266.70%
-0.09-71.22%
-0.32+101.95%
-0.16-110.64%
1.49+45.35%
1.03-359.67%
-0.40-50.60%
-0.80-157.97%
1.38-204.69%
-1.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomics Bioscience & Technology Co Stock analysis

What does Genomics Bioscience & Technology Co do? Genomics BioSci & Tech.Co., Ltd. generates revenue through the provision of public gene sequencing and clinical sequencing services, including preventive genetic testing, primer synthesis, and individualized medical and genetic screening for cancers. The company also manufactures and sells biochemical instruments, reagents, and consumables, distributing these products domestically and internationally. Its primary customers are healthcare providers and research institutions seeking genetic analysis and diagnostic solutions. The firm's services and products target both public health initiatives and specialized medical applications in oncology and preventive care. The company's revenue streams are derived from its core biotechnological services and product sales, with a focus on domestic and overseas markets. Public gene sequencing services cater to broader health screening needs, while clinical sequencing services address specific medical conditions, particularly cancer-related genetic screening. The firm's biochemical instruments and reagents support laboratory operations in both research and clinical settings, serving a diverse clientele across multiple healthcare segments. Genomics Bioscience & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomics Bioscience & Technology Co stock

Debt Service Coverage Ratio (DSCR) of Genomics Bioscience & Technology Co is -0.29 in 2025.

Debt Service Coverage Ratio (DSCR) of Genomics Bioscience & Technology Co changed from -0.34 to -0.29, representing a -15.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Genomics Bioscience & Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genomics Bioscience & Technology Co

All Key Metrics — Genomics Bioscience & Technology Co